DOCSLIB.ORG

Role of Interaction of CD2 Molecules with Lymphocyte Function

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Role of Interaction of CD2 Molecules with Lymphocyte Function Proc. Nadl. Acad. Sci. USA Vol. 87, pp. 2603-2607, April 1990 Immunology Role of interaction of CD2 molecules with lymphocyte function- associated antigen 3 in T-cell recognition of nominal antigen (cell adhesion/cytotoxic T cells/T-cell activation/T-cell receptor) SHIGEO KOYASU*t*, TREBOR LAWTON*, DAVID NovICK*, MICHAEL A. RECNY*§¶, ROBERT F. SILICIANO11, BARBARA P. WALLNER**, AND ELLIS L. REINHERZ*tt *Laboratory of Immunobiology, Dana-Farber Cancer Institute, and Departments of tPathology, ttMedicine, and 1Biological Chemistry & Molecular Pharmacology, Harvard Medical School, Boston, MA 02115; §Procept, Inc., Cambridge, MA 02139; 'Division of Molecular and Clinical Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD 21205; and **Biogen Research Corporation, Cambridge, MA 02142 Communicated by Max D. Cooper, January 3, 1990 (receivedfor review December 1, 1989) ABSTRACT The role of the interaction of CD2 molecules expressing human CD2 have suggested that CD2-LFA-3 with lymphocyte function-associated antigen 3 (LFA-3) in interaction is important for the T-cell recognition process (7, facilitating nominal antigen recognition by T lymphocytes was 8). However, virtually nothing is known about the mecha- studied by utilizing an HLA-DR4-restricted CD4+ cytotoxic nism by which CD2-LFA-3 interaction augments T-cell rec- human T-cell clone specific for human immunodeficiency virus ognition-in particular, whether the interaction influences envelope glycoprotein gpl20 as a responder and murine flbro- recognition of nominal antigen and whether this conjugate blasts transfected with human class II major histocompatibility pair interacts with TCR during the antigen recognition pro- complex (MHC) and/or human LFA-3 molecules as antigen- cess. To analyze the contribution of CD2-LFA-3 interaction presenting cells (APC). Although expression of the DR4 re- to T-cell recognition of nominal antigen, we have examined striction element in fibroblasts is sufficient for T-cell recogni- the nature of physiologic interactions between the CD4' tion of a gpl20 peptide asjudged by induction ofproliferation, HLA-DR4-restricted human cytotoxic T-cell clone Een- coexpression of human LFA-3 on DR4+ APC decreases the 217.5, which is specific for the H3DCG human immunode- molar requirement of nominal antigen by greater than one ficiency virus 1 envelope glycoprotein gp120 (9), and murine order ofmagnitude. Both LFA-3 and the relevant class H MHC fibroblasts into which human class II MHC restricting ele- molecules are necessary for antigen-independent conjugate ments and LFA-3 were selectively transfected. Such a sys- formation, but the binding is further enhanced by specific tem, in which only defined human molecules are expressed nominal antigen. CD2-LFA-3 interaction is independent of on antigen-presenting cells (APC), allows for a controlled T-cell receptor-MHC interaction and contributes directly to analysis of individual receptor-ligand pairs. the stabilized conjugate between the T cell and LFA-3-bearing APC; soluble CD2 and monoclonal antibodies to LFA-3 and CD2 reduce T-cell-APC binding to the level mediated by MATERIALS AND METHODS nominal antigen and MHC. During conjugate formation, CD2 Materials. A peptide corresponding to residues 410-429 of but not CD3 molecules are reorganized into the cell-cell gp120 ("gpl20 peptide") was synthesized on an Applied interaction site in an antigen-independent manner. Thus, re- Biosystems 431A automated peptide synthesizer and purified organization and/or coassociation of CD2 with CD3 molecules by reverse-phase HPLC using a Waters Deltapak C18 column. is not essential for T-cell activation. The secreted membrane anchor-lacking forms of CD2 and CD4 molecules were prepared in a baculovirus system as The ability ofT lymphocytes to recognize specific antigens in described (10, 11). The following monoclonal antibodies the context of class I and class II major histocompatibility (mAbs) were used in this study: Leu4 (anti-CD3); l9Thy5D7 complex (MHC) molecules is determined by the unique (anti-CD4); 3T4-8B5 (anti-T111); 1OLD24CI (anti-T112); 9-49 clonotypic T-cell receptor (TCR)-CD3 complex which they (directed against the common determinant of human class II individually bear. The process of antigen recognition in- MHC molecule); 11.4.1 (anti-murine H-2Kk); TS2/9.1.1 (an- volves the physical interaction of a TCR with a nominal ti-human LFA-3); fluorescein isothiocyanate (FITC)- peptide antigen bound to a specific MHC molecule referred conjugated 1OLD24C1; and tetramethylrhodamine isothio- to as a restricting element. This process is not singularly cyanate (TRITC)-conjugated Leu4. dictated by the TCR complex itself, but rather is dependent Cells and Growth Conditions. The CD4' CD8- human on other structures, including CD4, CD8, CD2, and lympho- T-lymphocyte clone Een217.5 is a subclone ofEen217 that is cyte function-associated antigen 1 (LFA-1) (reviewed in refs. specific for gpl20 in a DR4-restricted manner (9). Nomen- 1-3). CD4 and CD8 structures bind to monomorphic regions clature and phenotype of the murine L cell fibroblast trans- of class II and class I MHC structures, respectively, thereby fectants used as APC in this study are shown in Table 1. The facilitating the interaction of the TCR with the MHC restrict- preparation of murine L cell fibroblasts transfected with ing element (reviewed in ref. 4). In addition to the MHC full-length cDNA encoding human class II DR a and / chains binding accessory structures, a set of adhesion structures was described previously (9, 12). Those cells were further facilitates non-antigen-specific interactions between T lym- transfected with Xmn I-linearized animal expression plasmid phocytes and their cognate partners. This set includes the BG8/LFA-3, which contains the full-length cDNA for the CD2/lymphocyte function-associated antigen 3 (LFA-3) re- transmembrane form ofLFA-3, and Sca-I-linearized plasmid ceptor-ligand pair (5, 6). Studies employing antibodies directed against CD2 or Abbreviations: APC, antigen-presenting cell(s); FITC, fluorescein LFA-3 as well as murine T-cell hybridoma transfectants isothiocyanate; LFA-1, lymphocyte function-associated antigen 1; LFA-3, lymphocyte function-associated antigen 3; mAb, monoclonal antibody; MHC, major histocompatibility complex; TCR, T-cell The publication costs of this article were defrayed in part by page charge receptor; TRITC, tetramethylrhodamine isothiocyanate. payment. This article must therefore be hereby marked "advertisement" *On leave from: Tokyo Metropolitan Institute of Medical Science, in accordance with 18 U.S.C. §1734 solely to indicate this fact. Tokyo 113, Japan. 2603 Downloaded by guest on October 2, 2021 2604 Immunology: Koyasu et al. Proc. Natl. Acad. Sci. USA 87 (1990) Table 1. Phenotypes of L cell transfectants the human Een217.5 T-cell clone is cultured with the DR4+ Cell line Class II MHC LFA-3 LFA-3- murine L cell transfectant L89.2, it is stimulated to proliferate in expanding T-cell colonies and readily lyses L* - _ L89.2 only in the presence of specific peptide antigen derived L-HT16 - ++ from gpl20 of the human immunodeficiency virus H3DCG L17.8 DRw53t _ strain (Fig. 1). Using various L cell transfectants as APC, we L12.2 DR7 - examined the effect of CD2-LFA-3 interaction on the pro- L12.2.16 DR7 ++ liferative response of Een217.5 to gpl20 peptide at a range of L89.2 DR4 - concentrations. As shown in Fig. 2a, L89.2.1 could stimulate L89.2.11 DR4 proliferation of Een217.5 to the same degree as L89.2 but L89.2.1 DR4 ++ required <1/10th the molar concentration of peptide. *L cells were established from C3H/He mice (H-2k). L89.2.11, which expresses 1/5th the LFA-3 of L89.2.1, tExpression of class II MHC molecules among different positive stimulated Een217.5 at a lower concentration ofpeptide than transfectants was virtually identical except for L17.8, which ex- presses 1/5th the surface copy number. L89.2 but was less efficient than L89.2.1. As anticipated by tAll LFA-3 transfectants expressed virtually equivalent copy num- the MHC restriction of Een217.5, neither L cells nor L cell bers of surface LFA-3 except for L89.2.11, which expresses 1/5th transfectants L-HT16, L17.8, L12.2, and L12.2.16 induced the surface copy number. Een217.5 to proliferate even in the presence of 1,uM specific peptide (data not shown). Although not shown, Een217.5 also pOPF, which carries the thymidine kinase gene (13). Trans- lysed L89.2.1 at a decreased peptide concentration relative to fected cells were selected in Dulbecco's modified Eagle's L89.2. medium (DMEM)/10% (vol/vol) fetal calf serum (FCS) con- The enhanced proliferation of Een217.5 in response to a taining 100 ,uM hypoxanthine/0.4 mM aminopterin/16 ,M suboptimal concentration of peptide presented by L89.2.1 thymidine (HAT) and were further analyzed for expression of versus L89.2 is clearly a consequence of CD2-LFA-3 inter- surface LFA-3 as well as class II molecules by indirect action. As shown in Fig. 2b, when anti-LFA-3 mAb was immunofluorescence. added to the culture stimulated by antigen and L89.2.1, the Proliferation Assays. Proliferation assays using fibroblast proliferative response was reduced to the same level as the cells as APC were performed as follows. Fibroblasts were response induced by L89.2. In contrast, the same antibody incubated with DMEM/10% FCS containing mitomycin C at did not affect the proliferative response to peptide plus L89.2. 10 ,g/ml and 1 mM thymidine for 4 hr. After extensive mAbs against the endogenous L cell H-2Kk murine class I washing, the cells were trypsinized and plated into 96-well MHC molecules did not show any inhibitory effect. These flat-bottom plates (2 x 104 per well). Een217.5 cells (5 x 104 results indicate that expression of the relevant class II MHC per well) were stimulated with those fibroblasts in the pres- molecules on APC is sufficient for T-cell proliferation but that ence ofgpl20 peptide at various concentrations for 24 hr.
Load more

Recommended publications
  • Costimulation of T-Cell Activation and Virus Production by B7 Antigen on Activated CD4+ T Cells from Human Immunodeficiency Virus Type 1-Infected Donors OMAR K
    Proc. Natl. Acad. Sci. USA Vol. 90, pp. 11094-11098, December 1993 Immunology Costimulation of T-cell activation and virus production by B7 antigen on activated CD4+ T cells from human immunodeficiency virus type 1-infected donors OMAR K. HAFFAR, MOLLY D. SMITHGALL, JEFFREY BRADSHAW, BILL BRADY, NITIN K. DAMLE*, AND PETER S. LINSLEY Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, WA 98121 Communicated by Leon E. Rosenberg, August 3, 1993 (receivedfor review April 29, 1993) ABSTRACT Infection with the human immunodeficiency sequence (CTLA-4) (34), a protein structurally related to virus type 1 (HIV-1) requires T-cefl activation. Recent studies CD28 but only expressed on T cells after activation (12). have shown that interactions of the T-lymphocyte receptors CTLA-4 acts cooperatively with CD28 to bind B7 and deliver CD28 and CTLA-4 with their counter receptor, B7, on antigen- T-cell costimulatory signals (13). presenting cells are required for optimal T-cell activation. Here Because of the importance of the CD28/CTLA-4 and B7 we show that HIV-1 infection is associated with decreased interactions in immune responses, it is likely that these expression of CD28 and increased expression of B7 on CD4+ interactions are also important during HIV-1 infection. Stud- T-cell lines generated from seropositive donors by afloantigen ies with anti-CD28 monoclonal antibodies (mAbs) suggested stimulation. Loss of CD28 expression was not seen on CD4+ a role for CD28 in up-regulating HIV-1 long terminal repeat- T-ceU lines from seronegative donors, but up-regulation of B7 driven transcription of a reporter gene in leukemic cell lines expression was observed upon more prolonged culture.
    [Show full text]
  • Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse
    Welcome to More Choice CD Marker Handbook For more information, please visit: Human bdbiosciences.com/eu/go/humancdmarkers Mouse bdbiosciences.com/eu/go/mousecdmarkers Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse CD3 CD3 CD (cluster of differentiation) molecules are cell surface markers T Cell CD4 CD4 useful for the identification and characterization of leukocytes. The CD CD8 CD8 nomenclature was developed and is maintained through the HLDA (Human Leukocyte Differentiation Antigens) workshop started in 1982. CD45R/B220 CD19 CD19 The goal is to provide standardization of monoclonal antibodies to B Cell CD20 CD22 (B cell activation marker) human antigens across laboratories. To characterize or “workshop” the antibodies, multiple laboratories carry out blind analyses of antibodies. These results independently validate antibody specificity. CD11c CD11c Dendritic Cell CD123 CD123 While the CD nomenclature has been developed for use with human antigens, it is applied to corresponding mouse antigens as well as antigens from other species. However, the mouse and other species NK Cell CD56 CD335 (NKp46) antibodies are not tested by HLDA. Human CD markers were reviewed by the HLDA. New CD markers Stem Cell/ CD34 CD34 were established at the HLDA9 meeting held in Barcelona in 2010. For Precursor hematopoetic stem cell only hematopoetic stem cell only additional information and CD markers please visit www.hcdm.org. Macrophage/ CD14 CD11b/ Mac-1 Monocyte CD33 Ly-71 (F4/80) CD66b Granulocyte CD66b Gr-1/Ly6G Ly6C CD41 CD41 CD61 (Integrin b3) CD61 Platelet CD9 CD62 CD62P (activated platelets) CD235a CD235a Erythrocyte Ter-119 CD146 MECA-32 CD106 CD146 Endothelial Cell CD31 CD62E (activated endothelial cells) Epithelial Cell CD236 CD326 (EPCAM1) For Research Use Only.
    [Show full text]
  • Papers J Clin Pathol: First Published As 10.1136/Jcp.49.7.539 on 1 July 1996
    Clin Pathol 1996;49:539-544 539 Papers J Clin Pathol: first published as 10.1136/jcp.49.7.539 on 1 July 1996. Downloaded from Differential expression of T cell antigens in normal peripheral blood lymphocytes: a quantitative analysis by flow cytometry L Ginaldi, N Farahat, E Matutes, M De Martinis, R Morilla, D Catovsky Abstract diagnosis by comparison with findings in Aims-To obtain reference values of the normal counterparts. level of expression of T cell antigens on ( Clin Pathol 1996;49:539-544) normal lymphocyte subsets in order to disclose differences which could reflect Keywords: flow cytometry, T cell antigens, peripheral their function or maturation stages, or blood lymphocytes. both. Methods-Peripheral blood from 15 healthy donors was processed by flow The most common use of flow cytometry is to cytometry with triple colour analysis. For determine the percent of "positive" or "nega- each sample phycoerythrin (PE) conju- tive" cells for each antigen in different cell gated CD2, CD4, CD5, CD8, and CD56 populations. However, valuable information is monoclonal antibodies were combined lost when the relative intensities of the positive with Cy5-R-phycoerythrin (TC) conju- cells, reflecting antigenic densities, are not considered. A cell population with a well gated CD3 and fluorescein isothiocyanate http://jcp.bmj.com/ (FITC) conjugated CD7; CD2- and defined phenotype, positive for one antigen, CD7-PE were also combined with might be heterogeneous with regard to its level CD3-TC and CD4-FITC. Standard mi- of expression. This may reflect different crobeads with different capacities to bind functional or maturational states, or both, or mouse immunoglobulins were used to identify subpopulations on the basis of the dif- convert the mean fluorescence intensity ferent numbers of molecules of antigen per cell.
    [Show full text]
  • CD18) in a Patient with Leukocyte Adhesion Molecule (Leu-CAM) Deficiency
    Point mutations impairing cell surface expression of the common beta subunit (CD18) in a patient with leukocyte adhesion molecule (Leu-CAM) deficiency. M A Arnaout, … , D G Tenen, D M Fathallah J Clin Invest. 1990;85(3):977-981. https://doi.org/10.1172/JCI114529. Research Article The leukocyte adhesion molecules CD11a/CD18, CD11b/CD18, and CD11c/CD18 (Leu-CAM) are members of the integrin receptor family and mediate crucial adhesion-dependent functions in leukocytes. The molecular basis for their deficient cell surface expression was sought in a patient suffering from severe and recurrent bacterial infections. Previous studies revealed that impaired cell surface expression of Leu-CAM is secondary to heterogeneous structural defects in the common beta subunit (CD18). Cloning and sequencing of complementary DNA encoding for CD18 in this patient revealed two mutant alleles, each representing a point mutation in the coding region of CD18 and resulting in an amino acid substitution. Each mutant allele results in impaired CD18 expression on the cell surface membrane of transfected COS M6 cells. One substitution involves an arginine residue (Arg593----cysteine) that is conserved in the highly homologous fourth cysteine-rich repeats of other mammalian integrin subfamilies. The other substitution involves a lysine residue (Lys196----threonine) located within another highly conserved region in integrins. These data identify crucial residues and regions necessary for normal cell surface expression of CD18 and possibly other integrin beta subunits and define a molecular basis for impaired cell surface expression of CD18 in this patient. Find the latest version: https://jci.me/114529/pdf Rapid Publication Point Mutations Impairing Cell Surface Expression of the Common ,B Subunit (CD18) in a Patient with Leukocyte Adhesion Molecule (Leu-CAM) Deficiency M.
    [Show full text]
  • The Immunological Synapse and CD28-CD80 Interactions Shannon K
    © 2001 Nature Publishing Group http://immunol.nature.com ARTICLES The immunological synapse and CD28-CD80 interactions Shannon K. Bromley1,Andrea Iaboni2, Simon J. Davis2,Adrian Whitty3, Jonathan M. Green4, Andrey S. Shaw1,ArthurWeiss5 and Michael L. Dustin5,6 Published online: 19 November 2001, DOI: 10.1038/ni737 According to the two-signal model of T cell activation, costimulatory molecules augment T cell receptor (TCR) signaling, whereas adhesion molecules enhance TCR–MHC-peptide recognition.The structure and binding properties of CD28 imply that it may perform both functions, blurring the distinction between adhesion and costimulatory molecules. Our results show that CD28 on naïve T cells does not support adhesion and has little or no capacity for directly enhancing TCR–MHC- peptide interactions. Instead of being dependent on costimulatory signaling, we propose that a key function of the immunological synapse is to generate a cellular microenvironment that favors the interactions of potent secondary signaling molecules, such as CD28. The T cell receptor (TCR) interaction with complexes of peptide and as CD2 and CD48, which suggests that CD28 might have a dual role as major histocompatibility complex (pMHC) is central to the T cell an adhesion and a signaling molecule4. Coengagement of CD28 with response. However, efficient T cell activation also requires the partici- the TCR has a number of effects on T cell activation; these include pation of additional cell-surface receptors that engage nonpolymorphic increasing sensitivity to TCR stimulation and increasing the survival of ligands on antigen-presenting cells (APCs). Some of these molecules T cells after stimulation5. CD80-transfected APCs have been used to are involved in the “physical embrace” between T cells and APCs and assess the temporal relationship of TCR and CD28 signaling, as initiat- are characterized as adhesion molecules.
    [Show full text]
  • (12) United States Patent (405
    USOO6291239B1 (12) United States Patent (10) Patent No.: US 6,291,239 B1 Prodinger et al. (45) Date of Patent: Sep. 18, 2001 (54) MONOCLONAL ANTIBODY Recess Formed Between SCR1 and SCR 2 of Complement Receptor Type Two', Prodinger. (76) Inventors: Wolfgang Prodinger, Kirschentalgasse Immunopharmacology, vol. 38, No. 1-2, Dec., 1997, pp. 16, A-6020 Innsbruck; Michael 141-148, XP002089604, “Expression in Insect Cells of the Schwendinger, Semmelweisgasse 4, Functional Domain of CD21 (Complement Receptor Type A-7100 Neusiedl/See, both of (AT) Two) as a Truncated... ", Prodinger. Journal of Immunology, vol. 156, No. 7 Apr. 1, 1996, pp. (*) Notice: Subject to any disclaimer, the term of this 2580–2584, XP002089605, “Ligation of the Functional patent is extended or adjusted under 35 Domain of Complement Receptor Type 2 (CR2, CD21) is U.S.C. 154(b) by 0 days. Relevant for Complex . , Prodinger. Journal of Immunology, vol. 154, No. 10, May 15, 1995, pp. (21) Appl. No.: 09/276,296 5426–5435, XP002089606, “Characterization of a Comple (22) Filed: Mar. 25, 1999 ment Receptor 2 (CR2, CD21) Ligand Binding Site for C3”, H. Molina et al. (51) Int. Cl. ............................... C12N 5/06; C12O 1/70; Journal of Immunology, vol. 161, Nov. 1, 1998, pp. G01N 33/53; CO7K 16/00; A61K 39/395 4604–4610, XP002089607, “Characterization of C3dg Binding to a Recess Formed Between Short Consensus (52) U.S. Cl. ............................ 435/339.1; 435/5; 435/7.1; Repeats 1 and 2 ... ', Prodinger. 435/334; 530/388.1; 530/388.35; 424/141.1; 424/143.1; 424/159.1 Primary Examiner Hankyel T.
    [Show full text]
  • CD20-Positive Peripheral T-Cell Lymphoma: Report of a Case After Nodular Sclerosis Hodgkin’S Disease and Review of the Literature Renee L
    CD20-Positive Peripheral T-Cell Lymphoma: Report of a Case after Nodular Sclerosis Hodgkin’s Disease and Review of the Literature Renee L. Mohrmann, M.D., Daniel A. Arber, M.D. Division of Pathology, City of Hope National Medical Center, Duarte, California CASE REPORT We present a case of peripheral T-cell lymphoma co-expressing CD3 and CD20, as well as demon- A 47-year-old man presented in 1993 with a brief strating T-cell receptor gene rearrangement, in a history of right axillary lymph node enlargement patient who had been diagnosed with nodular scle- and mild fatigue. Biopsy showed nodular sclerosis rosis Hodgkin’s disease 5 years previously. Although Hodgkin’s disease. He was treated with six courses 15 cases of CD20-positive T-cell neoplasms have of mechlorethamine, vincristine, procarbazine, been previously reported in the literature, this is the prednisone/doxorubicin, bleomycin, vinblastine first report of CD20-positive T-cell lymphoma oc- chemotherapy over a period of 6 months. Clinical curring subsequent to treatment of Hodgkin’s dis- remission was achieved for 5 years. In early 1998, the patient noticed enlargement of lymph nodes in ease. The current case affords an opportunity to the posterior cervical region, which were followed review the rarely reported expression of CD20 in clinically for several months. Weight loss of 15 lbs., T-cell neoplasms as well as the relationship between fatigue, and flu-like symptoms ensued. The lymph Hodgkin’s disease and subsequently occurring non- nodes became firmer to palpation and were biop- Hodgkin’s lymphomas. In addition, the identifica- sied, showing peripheral T-cell lymphoma, diffuse tion of this case supports the suggestion that the use large-cell type.
    [Show full text]
  • Immunological Synapse Formation Licenses CD40-CD40L Accumulations at T-APC Contact Sites1
    The Journal of Immunology Immunological Synapse Formation Licenses CD40-CD40L Accumulations at T-APC Contact Sites1 Judie Boisvert, Samuel Edmondson, and Matthew F. Krummel2 The maintenance of tolerance is likely to rely on the ability of a T cell to polarize surface molecules providing “help” to only specific APCs. The formation of a mature immunological synapse leads to concentration of the TCR at the APC interface. In this study, we show that the CD40-CD154 receptor-ligand pair is also highly concentrated into a central region of the synapse on mouse lymphocytes only after the formation of the TCR/CD3 c-SMAC. Concentration of this ligand was strictly dependent on TCR recognition, the binding of ICAM-1 to T cell integrins and the presence of an intact cytoskeleton in the T cells. This may provide a novel explanation for the specificity of T cell help directing the help signal to the site of Ag receptor signal. It may also serve as a site for these molecular aggregates to coassociate and/or internalize alongside other signaling receptors. The Journal of Im- munology, 2004, 173: 3647–3652. uring the onset and propagation of immune responses, T Interactions of T cells with Ag-bearing APCs is associated with cells send and receive signals via Ag-dependent and Ag- a coalescence of TCRs, other related receptors such as CD2, CD4, independent ligands. Whereas peptide-class II MHC CD28, and signaling molecules such as p56lck, fyn, linker for ac- D ϩ complexes on APC are recognized by the TCR on CD4 helper T tivation of T cells, and protein kinase C␪ into the central portion of cells, separate cell surface receptors modulate T cell-APC inter- an “immunological synapse” (15–23).
    [Show full text]
  • Processing Epitope Precursor Recognition and Analogue Provides
    The Journal of Immunology Crystal Structure of Insulin-Regulated Aminopeptidase with Bound Substrate Analogue Provides Insight on Antigenic Epitope Precursor Recognition and Processing Anastasia Mpakali,* Emmanuel Saridakis,* Karl Harlos,† Yuguang Zhao,† Athanasios Papakyriakou,* Paraskevi Kokkala,*,‡ Dimitris Georgiadis,‡ and Efstratios Stratikos* Aminopeptidases that generate antigenic peptides influence immunodominance and adaptive cytotoxic immune responses. The mechanisms that allow these enzymes to efficiently process a vast number of different long peptide substrates are poorly understood. In this work, we report the structure of insulin-regulated aminopeptidase, an enzyme that prepares antigenic epitopes for cross- presentation in dendritic cells, in complex with an antigenic peptide precursor analog. Insulin-regulated aminopeptidase is found in a semiclosed conformation with an extended internal cavity with limited access to the solvent. The N-terminal moiety of the peptide is located at the active site, positioned optimally for catalysis, whereas the C-terminal moiety of the peptide is stabilized along the extended internal cavity lodged between domains II and IV. Hydrophobic interactions and shape complementarity enhance peptide affinity beyond the catalytic site and support a limited selectivity model for antigenic peptide selection that may underlie the generation of complex immunopeptidomes. The Journal of Immunology, 2015, 195: 2842–2851. ytotoxic adaptive immune responses rely on the recogni- process, and present external Ags onto MHCI to allow cross-priming tion on the cell surface of complexes of MHC class I of naive CD8+ T cells (2). The cross-presentation pathway is key for C molecules (MHCI) with antigenic peptides. These peptides the immune defense against many viruses, bacteria, and tumors and are generated inside the cell by proteolytic digestion that often can help the immune system avoid immune evasion strategies.
    [Show full text]
  • Efficient Generation of Human Natural Killer Cell Lines by Viral Transformation
    Letters to the Editor 192 2 Department of Immunology, Erasmus MC, Erasmus University selected children with hypoplastic refractory cytopenia. Haematologica 2007; 92: Medical Center, Rotterdam, The Netherlands; 397–400. 3Department of Pediatrics and Adolescent Medicine, Division of 4 Dunn DE, Tanawattanacharoen P, Boccuni P, Nagakura S, Green SW, Kirby MR Pediatric Hematology and Oncology, University of Freiburg, et al. Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow Freiburg, Germany; failure syndromes. Ann Intern Med 1999; 131: 401–408. 4Department of Pathology, Clinical Centre South West, Bo¨blingen 5 Maciejewski JP, Follmann D, Nakamura R, Saunthararajah Y, Rivera CE, Simonis T et al. Increased frequency of HLA-DR2 in patients with paroxysmal nocturnal Clinics, Bo¨blingen, Germany; 5 hemoglobinuria and the PNH/aplastic anemia syndrome. Blood 2001; 98: Department of Clinical Genetics, Erasmus MC, Erasmus University 3513–3519. Medical Center, Rotterdam, The Netherlands; 6 Wang H, Chuhjo T, Yasue S, Omine M, Nakao S. Clinical significance of a minor 6 St. Anna Children’s Hospital and Children’s Cancer Research Institute, population of paroxysmal nocturnal hemoglobinuria-type cells in bone marrow Department of Pediatrics, Medical University of Vienna, failure syndrome. Blood 2002; 100: 3897–3902. Vienna, Austria; 7 Yoshida N, Yagasaki H, Takahashi Y, Yamamoto T, Liang J, Wang Y et al. 7Department of Pediatrics, Aarhus University Hospital Skejby, Clinical impact of HLA-DR15, a minor population of paroxysmal Aarhus, Denmark; nocturnal haemoglobinuria-type cells, and an aplastic anaemia-associated auto- 8Department of Pediatric Hematology-Oncology, IRCCS Ospedale antibody in children with acquired aplastic anaemia. Br J Haematol 2008; 142: 427–435.
    [Show full text]
  • And CD28 (T P44) Induces Autocrine Interleukin 2/Interleukin 2 Receptor-Mediated Cell Proliferation
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by PubMed Central A NOVEL ACTIVATION PATHWAY FOR MATURE THYMOCYTES Costimulation of CD2 (T,p50) and CD28 (T p44) Induces Autocrine Interleukin 2/Interleukin 2 Receptor-mediated Cell Proliferation By SOO YOUNG YANG, STEPHEN M. DENNING,' SHINICHI MIZUNO, BO DUPONT, AND BARTON F. HAYNES* From the Laboratories of Human and Biochemical Immunogenetics, Sloan-Kettering Institute for Cancer Research, New York, New York 10021; and the "Department of Medicine, Division of Rheumatology, Immunology, and Cardiology, Duke University School of Medicine, Durham, North Carolina 27710 Bone marrrow-derived T progenitor cells undergo proliferation and maturation under the influence of the thymic microenvironment (1). Only a small fraction of thymocytes are selected to account for self tolerance, as well as self restriction, and become immunocompetent T cells (2). The molecular and cellular mechanisms for the growth and maturation of thymocytes are poorly understood. Cell surface phenotype analyses have shown that thymocytes are composed ofhighly heterogeneous populations. Based on cell surface expression of the TCR accessory molecules CD4 and CD8, thymocytes can be divided into three major subpopula- tions, which generally are thought to relate to maturation stages. They are the CD2+CD1 - CD4- 8- (double-negative) cells, CD2'CD1'CD4'8' (double-positive) cells, and CD2' CDl - CD4' 8- or CD2' CDl - CD4- 8' (single-positive) mature thymocytes. Both double-negative and double-positive thymocytes are immature cells located in the cortical compartment of human thymus (3). Mature thymocytes do not express the cortical specific marker CD1 but express TCRA and B chain subunits associated with the CD3 complex and reside predominantly in the medullary com- partment (4) .
    [Show full text]
  • Integrins As Therapeutic Targets: Successes and Cancers
    cancers Review Integrins as Therapeutic Targets: Successes and Cancers Sabine Raab-Westphal 1, John F. Marshall 2 and Simon L. Goodman 3,* 1 Translational In Vivo Pharmacology, Translational Innovation Platform Oncology, Merck KGaA, Frankfurter Str. 250, 64293 Darmstadt, Germany; [email protected] 2 Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK; [email protected] 3 Translational and Biomarkers Research, Translational Innovation Platform Oncology, Merck KGaA, 64293 Darmstadt, Germany * Correspondence: [email protected]; Tel.: +49-6155-831931 Academic Editor: Helen M. Sheldrake Received: 22 July 2017; Accepted: 14 August 2017; Published: 23 August 2017 Abstract: Integrins are transmembrane receptors that are central to the biology of many human pathologies. Classically mediating cell-extracellular matrix and cell-cell interaction, and with an emerging role as local activators of TGFβ, they influence cancer, fibrosis, thrombosis and inflammation. Their ligand binding and some regulatory sites are extracellular and sensitive to pharmacological intervention, as proven by the clinical success of seven drugs targeting them. The six drugs on the market in 2016 generated revenues of some US$3.5 billion, mainly from inhibitors of α4-series integrins. In this review we examine the current developments in integrin therapeutics, especially in cancer, and comment on the health economic implications of these developments. Keywords: integrin; therapy; clinical trial; efficacy; health care economics 1. Introduction Integrins are heterodimeric cell-surface adhesion molecules found on all nucleated cells. They integrate processes in the intracellular compartment with the extracellular environment. The 18 α- and 8 β-subunits form 24 different heterodimers each having functional and tissue specificity (reviewed in [1,2]).
    [Show full text]